Heart Transplantation Clinical Trial
Official title:
The Evolution of Systemic Microvascular Reactivity in Heart Transplant Patients
The evolution of systemic microvascular reactivity may aid in the comprehension of cardiovascular physiology in heart transplantation patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients.
Introduction: Systemic microvascular reactivity (MR) is an essential component of cardiovascular physiology, being studied through non-invasive techniques in readily accessible body regions, such as the skin surface. Heart transplant (HT) is a treatment considered to selected patients, with advanced heart failure. The main cause of long-term mortality after HT is graft vascular disease (GVD), a condition which starts with endothelial dysfunction. To know the evolution of systemic MR in patients subjected to HT can help to find prognostic factors. Objective: The present study aims to perform the prospective evaluation of systemic MR in adult patients, before and two years after HT, at a quaternary hospital, correlating the findings with clinical variables. Methods: Systemic MR will be evaluated in the skin of the forearm using laser speckle contrast imaging with acetylcholine (ACh) iontophoresis, followed by postocclusive reactive hyperemia (PORH), before and after HT. Measurements will be correlated to patient clinical profile, hemodynamic and echocardiographic data. Expected results: The evolution of systemic MR may aid in the comprehension of cardiovascular physiology in HT patients, and possibly suggest the non-invasive evaluation of skin microcirculation as an ancillary tool in the clinical evaluation of these patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06035991 -
First Clinical Evaluation of Heart Transplantation With Grafts Preserved Using an Ex-vivo Extended Perfusion System
|
N/A | |
Recruiting |
NCT01927614 -
Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy
|
N/A | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Completed |
NCT01028599 -
Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients
|
N/A | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Terminated |
NCT00420537 -
Shift to Everolimus (RAD) Kidney Sparing Study
|
Phase 4 | |
Enrolling by invitation |
NCT03292861 -
The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT04924491 -
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05270902 -
Haemoadsorption During Heart Transplantation
|
N/A | |
Completed |
NCT05289180 -
Brachial Right Ventricle - Endomyocardial Biopsy
|
||
Recruiting |
NCT03687723 -
Observational Study of the Clinical Use of the OCS™ Heart
|
||
Completed |
NCT01091194 -
Effect of Exercise After Heart Transplantation
|
Phase 2 | |
Withdrawn |
NCT00780637 -
Brachial Artery t-PA Release in Heart Transplant Recipients
|
N/A | |
Completed |
NCT01182571 -
Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients
|
N/A | |
Withdrawn |
NCT00780377 -
Intracoronary Bradykinin Mediated t-PA Release in Heart Transplant Recipients
|
N/A | |
Terminated |
NCT00678002 -
Quality of Life in Pediatric Transplant Patients
|
||
Terminated |
NCT00121784 -
Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients
|
Phase 4 | |
Withdrawn |
NCT00572286 -
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
|
N/A | |
Completed |
NCT00123331 -
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
|
Phase 4 |